Teva Shares Hit 10-Year High Following FDA Approval for Schizophrenia Drug

Teva Pharmaceutical Industries shares surged on Friday, returning to the price levels last seen a decade ago. It has taken the Israeli pharmaceutical giant ten years to recover from the crippling crisis triggered by its acquisition of Actavis for nearly 40 billion dollars.

The leveraged acquisition, spearheaded by former CEO Erez Vigodman, burdened Teva with massive debt that threatened its very existence. This forced the company into an aggressive restructuring program under former CEO Kare Schultz, which included mass layoffs and plant closures to stabilize operations.

Current CEO Richard Francis took the helm in 2023 with a mandate to pivot Teva toward sustainable growth. Francis launched the "pivot to growth" strategic plan, focusing on accelerating innovation and proprietary drug development to transition Teva into a pure-play biopharma leader.

Proprietary Pipeline Targeting 10 Billion Dollars in Annual Revenue

Historically known as a generics powerhouse, Teva is now rapidly building a robust proprietary pipeline with a combined peak revenue potential exceeding 10 billion dollars annually. A milestone achievement arrived on Friday when the FDA approved WELTRUZA (olanzapine), a monthly long-acting injectable for adults with schizophrenia.

WELTRUZA represents a major therapeutic advancement, providing a monthly treatment option that significantly reduces symptom severity and improves personal and social functioning. Dr. Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer at Teva, stated that the approval reflects the company's patient-centric innovation capabilities.

Beyond schizophrenia, Teva's late-stage pipeline features several high-potential assets. These include treatments for asthma, vitiligo, and celiac disease, each projected to reach peak sales of up to 2 billion dollars. Meanwhile, duvakitug (anti-TL1A), developed in partnership with Sanofi for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, enters Phase 3 trials with estimated peak sales ranging between 2 billion and 5 billion dollars.

Market Response and Financial Recovery

Teva's market capitalization on the New York Stock Exchange currently stands at 47.9 billion dollars, reclaiming its historical status as the most valuable Israeli company on local indices. Wall Street reacted enthusiastically to the FDA approval and broader operational turnaround.

"The FDA approval of WELTRUZA marks a significant milestone for Teva's proprietary pipeline and grants the company a distinct competitive advantage in long-acting therapies," Oppenheimer analysts noted.

Following the regulatory green light, JPMorgan raised its price target for Teva stock from 40 dollars to 50 dollars with an "overweight" rating. Jefferies also upgraded its price target to 48 dollars, anticipating another strong quarterly earnings report as Teva successfully shakes off its legacy debt and returns to strategic acquisitions.